Weekly 20/56 mg/m² carfilzomib, lenalidomide and dexamethasone until progression in early relapsed refractory multiple myeloma

Maintenance with weekly carfilzomib in elderly newly diagnosed multiple myeloma

Proton therapy or photon therapy as part of concurrent chemoradiotherapy for locally advanced cancer

Olaparib and durvalumab in metastatic BRCA wild type triple-negative breast cancer

CASSIOPEIA: Daratumumab plus D-VTd vs VTd in transplant-eligible NDMM

Clinical activity and tolerability of the RET inhibitor BLUE-667 in patients with advanced RET fusion and NSCLC

Highlights from ASCO 2019

Potential of PARP inhibitors for metastatic breast cancer

Targeting agent enfortumab vedotin a novel treatment for patients with advanced urothelial cancer

New agent targeting Nectin-4 produces responses in nearly half of patients with advanced urothelial cancer

PARP inhibitor olaparib as treatment for pancreatic cancer patients with BRCA gene mutations

Enzalutamide as treatment for men with mHSPC who have received testosterone suppression